Selexipag Market Regional Analysis, Demand Analysis and Competitive Outlook 2025-2032

Market Overview

The global Selexipag market was valued at USD 1.67 billion in 2024 and is projected to reach USD 4.12 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 14.1% during the forecast period. This growth trajectory significantly outpaces the broader pharmaceutical market, which expanded at a 5% CAGR in 2022.

Selexipag is a selective prostacyclin receptor agonist used to treat pulmonary arterial hypertension (PAH), a rare but life-threatening condition characterized by high blood pressure in the arteries of the lungs. As an oral therapy, it offers improved patient compliance compared to traditional intravenous treatments. The drug works by dilating pulmonary arteries and preventing blood vessel remodeling, addressing both symptoms and disease progression.

USD 4.12 billion by 2031 USD 1.67 billion in 2024

of 14.1%

The global Selexipag market was valued at 1674 million USD in 2024 and is projected to reach 4120 million USD by 2031, growing at a compound annual growth rate (CAGR) of 14.1% during the forecast period. Selexipag, a selective IP prostacyclin receptor agonist, is primarily used in tablet form to manage pulmonary arterial hypertension (PAH), a chronic and progressive condition affecting the pulmonary vasculature. This growth is driven by increasing prevalence of PAH worldwide, advancements in targeted therapies, and rising awareness of oral treatments over injectables. The market is segmented based on type into:

0.2Mg 0.4Mg 0.8Mg

By Application

Within the broader pharmaceutical landscape, the global market reached 1475 billion USD in 2022, with projections for a CAGR of 5% over the next six years, fueled by demand for healthcare innovations and chronic disease management.

Selexipag's role in PAH treatment aligns with these trends, offering a noninvasive alternative that enhances patient compliance. The market is segmented based on application into:

Hospital Clinic

Other